Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Update

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 15,340,000 shares, a decrease of 21.8% from the April 30th total of 19,610,000 shares. Currently, 13.4% of the shares of the company are short sold. Based on an average daily volume of 2,630,000 shares, the short-interest ratio is presently 5.8 days.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DVAX shares. The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. JMP Securities reduced their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Dynavax Technologies presently has a consensus rating of "Hold" and a consensus target price of $24.00.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC purchased a new position in Dynavax Technologies in the fourth quarter valued at approximately $275,000. Barclays PLC boosted its position in Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after buying an additional 175,118 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Dynavax Technologies by 97.6% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock worth $3,964,000 after purchasing an additional 153,302 shares during the period. First Trust Advisors LP purchased a new stake in Dynavax Technologies in the fourth quarter worth about $847,000. Finally, Deep Track Capital LP lifted its holdings in shares of Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after purchasing an additional 5,265,000 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX traded up $0.17 during midday trading on Tuesday, reaching $10.01. 1,731,553 shares of the company were exchanged, compared to its average volume of 2,200,165. The stock has a market cap of $1.20 billion, a P/E ratio of 55.61 and a beta of 1.26. The stock's 50-day moving average price is $10.85 and its 200-day moving average price is $12.28. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a one year low of $9.22 and a one year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, sell-side analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.